How to Qualify for Ketamine Therapy in Canada

Key takeaways

• Primary indication: treatment-resistant depression (failure of at least 2 antidepressant trials at adequate dose for 6+ weeks each).
• Other indications: PTSD, anxiety disorders, OCD, bipolar depression, chronic pain (CRPS, neuropathic).
• Absolute contraindications: active psychosis, uncontrolled severe hypertension, severe cardiovascular disease, current pregnancy, anaphylactic reaction to ketamine, active manic episode.
• Most private Canadian clinics accept self-referrals. Some publicly funded programs require physician referral.
• Provincial regulator rules govern where IV ketamine can be administered (CPSA Alberta, CPSM Manitoba, CPSO Ontario, CPSBC BC).

Why qualifying matters before you book

Ketamine therapy is a medical treatment with specific clinical indications, real contraindications, and provincial regulatory rules about where and how it can be administered. Eligibility is a clinical decision made by a licensed prescriber after assessment, not a pre-approval you can self-determine. This guide walks through the criteria most Canadian clinics use so you can self-orient before your first call. The information call itself is the first formal qualification step.

What conditions qualify you for ketamine therapy?

The strongest evidence base — and the most common reason Canadian clinics accept patients — is treatment-resistant major depressive disorder (TRD). CANMAT 2021 lists IV racemic ketamine as a third-line treatment for adults with TRD (Swainson et al., 2021). Other commonly accepted indications:

• Major depressive disorder (non-TRD) — case-by-case, typically after first-line antidepressant trials
• Bipolar depression — with concurrent mood stabilizer coverage; supported by RCTs (Diazgranados et al., 2010; Zarate et al., 2012)
• Acute suicidal ideation — meta-analytic support for rapid reduction (Wilkinson et al., 2018)
• PTSD — RCT support for both single and repeated dosing (Feder et al., 2014, 2021)
• Anxiety disorders (social anxiety, generalized anxiety) — emerging RCT data
• OCD — small RCT evidence
• Chronic pain (CRPS, refractory neuropathic pain) — pain medicine specialist territory

Most clinics follow CANMAT or related Canadian clinical guidelines as their reference framework.

Atomic answer. Adults 18+ diagnosed with treatment-resistant depression — meaning at least two adequate antidepressant trials have not provided sufficient relief — are the primary candidates for ketamine therapy in Canada. Bipolar depression, PTSD, anxiety disorders, OCD, and certain chronic pain conditions may also qualify, subject to clinical screening.

What does "treatment-resistant" actually mean?

The CANMAT 2021 definition: failure of at least two adequate antidepressant trials from different pharmacological classes, plus at least one adjunctive medication trial. "Adequate" means the minimum recommended therapeutic dose per product monograph for at least 6 weeks per trial.

You do not need a formal "TRD" diagnosis from your GP before your first information call. Most Canadian clinics will evaluate your treatment history during intake. What helps speed the assessment:

• A list of every antidepressant you've tried (names, doses, durations, why each was discontinued)
• Any documented psychiatric assessment from a psychiatrist or family physician
• A summary of any psychotherapy you've completed
• Recent blood pressure readings if you have known hypertension

Do you qualify? A self-assessment checklist

This checklist is for self-orientation — formal eligibility is determined by a licensed clinician at intake. Most Canadian clinics use criteria similar to the following.

You may be a strong candidate if:

• You are 18 years of age or older (some clinics 19+ depending on province)
• You have a diagnosed mental-health or chronic-pain condition matching the indications above
• You have tried at least two antidepressants (for depression) without adequate relief
• Your blood pressure is reasonably controlled
• You have no active psychosis or current manic episode
• You are not currently pregnant or breastfeeding
• You do not have a known anaphylactic reaction to ketamine
• You have access to a designated driver for sessions

Bring up at intake — these are not automatic disqualifiers, but require clinical review:

• History of substance use disorder (especially ketamine specifically)
• Cardiovascular conditions (recent MI, valvular disease, aneurysm, untreated hypertension)
• Severe liver or kidney disease
• Current use of MAOIs, high-dose benzodiazepines, or naltrexone
• History of severe personality disorder with marked instability
• Recent stroke (under 6 months)
• Untreated severe sleep apnea
• Uncontrolled thyroid disease
• BMI over 35 (clinic-specific)

What disqualifies you from ketamine therapy?

Absolute contraindications rule out treatment at most Canadian clinics:

• Active psychosis or schizophrenia spectrum disorder
• History of severe psychotic episodes (inadequately treated)
• Untreated or poorly controlled severe hypertension
• Severe cardiovascular disease — recent MI within 6 weeks, decompensated heart failure (NYHA Class III–IV), significant valvular disease, central aneurysmal disease
• Increased intracranial pressure
• Severe hepatic insufficiency
• Active manic or mixed episode
• Current pregnancy
• Anaphylactic or hypersensitivity reaction to ketamine
• Active ketamine use disorder

Relative contraindications require careful evaluation but do not automatically exclude:

• Active substance use disorder (other substances) — most clinics require a stabilization period (3–6 months) and case-by-case review
• Severe personality disorder with marked instability
• Severe untreated bipolar I disorder (without mood stabilizer)
• Recent stroke (under 6 months)
• Untreated severe sleep apnea
• Hyperthyroidism (uncontrolled)
• Breastfeeding
• Concurrent use of medications that interact pharmacodynamically — particularly high-dose benzodiazepines (may attenuate antidepressant effect, Andrashko et al., 2021) and MAOIs (theoretical hypertensive risk; case reports reassuring with caution)

These criteria align with the APA Consensus Statement on Ketamine in Mood Disorders (Sanacora et al., 2017), CANMAT 2021, and the Edmonton community ketamine program protocol (Chrenek et al., 2024).

The ketamine therapy eligibility assessment, step by step

The path from "I want to try this" to "first session booked" typically follows six steps:

1. Information call. A brief intake call to confirm initial eligibility and explain the process.
2. Intake questionnaire. Online health-history form covering psychiatric history, medications, physical health, prior treatments. Submitted before the formal assessment.
3. Clinical consultation. A 45–60 minute video or in-person consultation with a physician, psychiatrist, or NP. Diagnostic confirmation, treatment-failure documentation, contraindication screening, suicide risk assessment.
4. Medical clearance. Cardiovascular workup including baseline blood pressure (both arms), heart rate, and ECG. CANMAT 2021 mandates ECG before infusion. For IV protocols, an anaesthesiologist may review cardiac history. Liver function may be assessed at baseline.
5. Informed consent and treatment plan. If cleared, a treatment plan is proposed (number of sessions, modality, integration approach). Consent is documented in writing. The plan covers dissociative and psychotomimetic effects during sessions, transient blood pressure elevation, the absence of long-term durability data for repeat infusions, dependency risk if used outside supervised settings, post-session driving restrictions.
6. First session scheduled. Most private Canadian clinics move from initial inquiry to first session within 2 to 4 weeks once cleared.

Eligibility by province — key differences

Provincial physician colleges set rules for where and how ketamine can be administered. These rules affect access pathways but do not generally change clinical eligibility criteria.

For ATMA CENA's specific provincial coverage, see the Calgary and Edmonton clinic pages, the Winnipeg member clinic, and the member-clinic network for other cities.

What to bring to your screening appointment

Five items help the clinical team make a faster, more accurate eligibility determination:

1. Medication list. Every current medication with dose, duration, and prescribing physician.
2. Prior treatment history. Antidepressants tried, doses, duration of each, reasons for discontinuation. For TRD documentation, this is the load-bearing piece.
3. Existing assessments. Any psychiatric assessment letters, GP referral notes, or specialist consult reports.
4. Recent blood pressure readings if you have known hypertension.
5. Questions for the clinician. Write them down; the call moves quickly.

What if I don't qualify right now?

Not qualifying at first assessment does not always mean "never." Common reasons for deferral and what they mean:

• Need to optimize blood pressure first. Work with your GP or cardiologist; reassess when controlled.
• Need to taper or modify a current medication. Common with high-dose benzodiazepines or naltrexone.
• Need to stabilize a co-occurring condition. Active mania, recent psychotic episode, recent stroke — these typically have a stabilization or wait period before reassessment.
• Need additional antidepressant trial first. If you haven't yet completed two adequate trials, your prescriber may recommend that first.
• Active substance use that needs stabilization. Most clinics ask for 3–6 months of stability.
• Geographic access. ATMA CENA delivers in-person at Calgary and Edmonton; member clinics serve other cities. If you're outside those service areas, ask about coordinated care network access during the call.

If ketamine therapy is not the right fit, the call team can speak to general therapy, rTMS, and other evidence-based options.

Frequently asked questions

Do I need a doctor's referral to get ketamine therapy in Canada?

How many antidepressants do I need to have tried to qualify? CANMAT defines TRD as failure of at least two antidepressant trials from different classes plus at least one adjunctive medication, each at adequate dose for 6+ weeks. Many Canadian patients in ketamine programs have tried significantly more.

Can I qualify for ketamine therapy for anxiety alone? Possibly. Ketamine has emerging RCT evidence for treatment-refractory social and generalized anxiety. Most Canadian clinics evaluate anxiety candidacy case-by-case. Some require depression to be the primary indication; others accept anxiety as primary.

How long does a ketamine eligibility assessment take? The information call is 15 minutes. The full clinical consultation is typically 45–60 minutes. From initial inquiry to first session, most private clinics move within 2–4 weeks.

What happens if I don't qualify right now? The clinical team will explain why and what would change the assessment — optimizing a co-condition, completing additional treatment trials, stabilization of substance use. Reassessment is possible after the underlying issue is addressed.

Is ketamine therapy safe for older adults? Yes, with proper screening. Cardiovascular workup is more important. The Edmonton public ketamine program serves adults across age ranges. CANMAT does not set an upper age limit.

Can I qualify if I have a history of substance use? Possibly, with stabilization. Active substance use disorder is a relative contraindication; most clinics ask for 3–6 months of stability. Active ketamine use disorder is an absolute contraindication.

Do I need to be in Alberta to access ATMA CENA? No. ATMA CENA operates corporate clinics in Edmonton and Calgary plus a member-clinic network across Canada including Winnipeg, Saskatoon, London, Hamilton, Mississauga, Vaughan, North Bay, Sarnia, Oakville, Kitchener-Waterloo, Windsor, and Montreal. The information call helps map you to the right access point.

What if I'm a veteran or WCB claimant? Veterans Affairs Canada covers ketamine for service-related TRD or chronic pain on a case-by-case basis. WCB Alberta and WSIB Ontario cover ketamine for compensable injuries with prior authorization. See Workers' Compensation Coverage in Alberta.

What does informed consent cover? The dissociative experience during sessions, transient blood pressure and heart rate elevation, post-session driving restrictions (24 hours), absence of long-term durability data for repeat infusions, dependency risk if ketamine is used outside supervised settings, and the off-label status of generic ketamine for psychiatric indications in Canada.

Sources

1. ATMA CENA — New Clients: https://psychedelic.healthcare/
2. ATMA CENA — Are You Ready: https://psychedelic.healthcare/
3. ATMA CENA — Workers' Compensation: https://psychedelic.healthcare/
4. ATMA CENA — Alberta Blue Cross Coverage: https://psychedelic.healthcare/
5. CPSA Alberta — Ketamine Prescribing Guidance (March 2026): https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
6. CPSM Manitoba — Ketamine Prescribers Guide (January 2026): https://www.cpsm.mb.ca/news/ketamine-what-prescribers-and-pharmacists-need-to-know
7. CPSBC British Columbia — Interim Ketamine Guidance (August 2025): https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
8. CPSO Ontario — OHPIP: https://www.cpso.on.ca/physicians/your-practice/accreditation-programs/out-of-hospital-premises-inspection-program/out-of-hospital-premises-inspection-program-overvi
9. Health Canada SAP Notice (psychedelic context for completeness): https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
10. Berman RM, et al. (2000). Antidepressant effects of ketamine. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/10686270/
11. Zarate CA Jr, et al. (2006). Ketamine in TRD. Arch Gen Psychiatry. https://pubmed.ncbi.nlm.nih.gov/16894061/
12. Diazgranados N, et al. (2010). Ketamine in bipolar depression. Arch Gen Psychiatry. https://pubmed.ncbi.nlm.nih.gov/20679587/
13. Zarate CA Jr, et al. (2012). Replication ketamine in bipolar depression. Biol Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC3343177/
14. Feder A, et al. (2014). Ketamine for chronic PTSD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/24499017/
15. Wilkinson ST, et al. (2018). Ketamine on suicidal ideation meta-analysis. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29064903/
16. Sanacora G, Frye MA, McDonald W, et al. (2017). APA Consensus Statement on the use of ketamine in mood disorders. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/28249076/
17. Swainson J, et al. (2021). CANMAT racemic ketamine recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
18. Andrashko V, et al. (2021). Ketamine drug interactions systematic review. Int J Neuropsychopharmacol. https://pmc.ncbi.nlm.nih.gov/articles/PMC8538895/
19. Chrenek C, et al. (2024). Edmonton community ketamine program. Front Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full

Related articles

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Ketamine Therapy Cost in Canada
• Ketamine Therapy for Depression
• Ketamine Therapy in Calgary
• Ketamine Therapy in Edmonton
• Workers' Compensation Coverage for Psychedelic Therapy in Alberta
• Alberta Blue Cross Coverage for Psychedelic Therapy
• Insurance Coverage for Ketamine Therapy

Last updated: 2026-05-05